Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma

NCT04005690 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT04005690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04005690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 1
Overall status
Recruiting
Start date
August 1, 2019
Completion date
February 1, 2028
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable pancreatic ductal adenocarcinoma, locally advanced pancreatic ductal adenocarcinoma, metastatic pancreatic ductal adenocarcinoma, resectable pancreatic ductal adenocarcinoma, stage ii pancreatic cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iv pancreatic cancer ajcc v8, unresectable pancreatic ductal adenocarcinoma